Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass.

In this study, we evaluated the biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass (CPB). Eight patients were divided into 2 groups: the control group (Group C) and heparin-coated group (Group H). In Group H, CPB circuits, including the arterial pump, oxygenator, and cannulas were heparin-coated. Before, during, and after CPB, blood samples were obtained to assess the platelet counts (Plat), alpha 2-plasmin plasminogen inhibitor complex (PIC), thrombin-antithrombin III complex (TAT), C3 activation products (C3a), interleukin (IL)-6, IL-8, and polymorphonuclear neutrophil leukocyte (PMN) elastase. There was no significant difference in Plat, PIC, or TAT between groups. Group H showed significantly low levels of C3a (during and after CPB), PMN elastase (during CPB), and IL-6 (after CPB). These data demonstrated that in pediatric CPB, heparin-coated CPB circuits reduced the activation of complements and the production of PMN elastase and IL-6, suggesting the superior biocompatibility of the heparin-coated circuits.

[1]  P. Venge,et al.  Reduced granulocyte activation with a heparin-coated device in an in vitro model of cardiopulmonary bypass. , 2008, Artificial organs.

[2]  H. Matsuda,et al.  Normothermia has beneficial effects in cardiopulmonary bypass attenuating inflammatory reactions. , 1995, ASAIO journal.

[3]  W. Wagner,et al.  Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss. , 1994, The Annals of thoracic surgery.

[4]  E. Fosse,et al.  Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. , 1994, The Annals of thoracic surgery.

[5]  G. von Bernuth,et al.  Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure. , 1993, The Journal of thoracic and cardiovascular surgery.

[6]  J. Weiler,et al.  Cytokine and complement levels in patients undergoing cardiopulmonary bypass. , 1993, The Journal of thoracic and cardiovascular surgery.

[7]  W. van Oeveren,et al.  Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[8]  M. Elliott,et al.  Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass. , 1993, The Journal of thoracic and cardiovascular surgery.

[9]  P. Venge,et al.  Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. , 1992, The Journal of thoracic and cardiovascular surgery.

[10]  E. Fosse,et al.  Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. , 1992, The Journal of thoracic and cardiovascular surgery.

[11]  J. Pincemail,et al.  Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans. , 1991, The Journal of thoracic and cardiovascular surgery.

[12]  W. van Oeveren,et al.  Heparin-coating of extracorporea circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass , 1991 .

[13]  D. Noonan,et al.  C5a-mediated release of interleukin 6 by human monocytes. , 1990, Clinical immunology and immunopathology.

[14]  W. W. Bailey,et al.  Complement activation and lung permeability during cardiopulmonary bypass. , 1990, The Annals of thoracic surgery.

[15]  E. Blackstone,et al.  Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. , 1986, The Annals of thoracic surgery.

[16]  S Westaby,et al.  Complement and the damaging effects of cardiopulmonary bypass. , 1983, The Journal of thoracic and cardiovascular surgery.

[17]  D. Stroncek,et al.  Complement activation and neutropenia occurring during cardiopulmonary bypass. , 1981, The Journal of thoracic and cardiovascular surgery.

[18]  R S Kronenberg,et al.  Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. , 1977, The New England journal of medicine.

[19]  H. Maurer,et al.  Impairment in platelet aggregation in congenital heart disease. , 1972, Blood.

[20]  H. Matsuda,et al.  Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations. , 1996, The Journal of thoracic and cardiovascular surgery.

[21]  B. Smith,et al.  Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. , 1994, The Journal of thoracic and cardiovascular surgery.

[22]  W. van Oeveren,et al.  Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass. , 1994, The Journal of thoracic and cardiovascular surgery.

[23]  R. Larsson,et al.  A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. , 1983, Biomaterials, medical devices, and artificial organs.